A new target action date has been set as the FDA continues to consider approving lifileucel for the treatment of advanced melanoma.
Nichole Tucker
Articles by Nichole Tucker
There are 2 new FDA indications for temozolomide.
A phase 1/2 study of tulmimetostat in patients with advanced solid tumors and lymphomas is underway.
In an interview, John Lister, MD, discussed the utility of stem cell transplant in T-cell lymphoma, including ongoing clinical trials and future needs.
According to Ruben A. Mesa, MD, FACP, confirming the benefit of long-acting interferon for essential thrombocytopenia is key.
Trilaciclib was found to to be a promising new treatment for chemotherapy-induced myelosuppression prevention and other benefits for patients with extensive-stage small cell lung cancer.
The first randomized study of immune checkpoint inhibitor therapy in platinum-sensitive ovarian cancer has missed its key end point.
On the heels of positive results from GENESIS, a phase 3 study, the FDA has approved the first stem cell mobilization therapy for multiple myeloma.
Roland Walter, MD, PhD, and Johannes Schetelig, MD, debated on the sequencing of allogeneic stem cell transplant in patients with relapsed or refractory acute myeloid leukemia.
In an interview with Targeted Oncology, Marcia S. Brose, MD, PhD, FASCO discussed the impact of selpercatinib in thyroid cancer, and what to expect from the drug in the future.
At the 11th Annual Meeting of the Society of Hematologic Oncology, a debate was held between Angela Dispenzieri, MD, and Sagar Lonial, MD, FACP, about treatment decisions for smoldering multiple myeloma.
The phase 3 MARIPOSA-2 study has met its primary end point.
Interim analysis results from a study of fostroxacitabine bralpamide plus lenvatinib show positive preliminary efficacy and safety.
Further data support the recent accelerated FDA approval of tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.
In the interview, Alexander Helfand, MD reviewed the latest in gastrointestinal stromal tumor research, and hopes for the future.
No significant difference in efficacy outcomes were shown with bintrafusp alfa vs pembrolizumab in patients with PD-L1-high, advanced non–small cell lung cancer. However, further investigation may offer more information about the benefit of this drug class.
In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.
Fam-trastuzumab deruxtecan-nxki was granted 2 breakthrough therapy designations by the FDA for its potential to fill a treatment gap for HER2-expressing tumors.
RefleXion X1 is now being used at City of Hope Comprehensive Cancer Center.
A retrospective study found no additional benefit for patients with non–small cell lung cancer who continued immunotherapy beyond 2 years.
The FDA has added to the existing approval of luspatercept-aamt for the treatment of patients with anemia and lower-risk myelodysplatic syndrome.
Treatment with an investigational mitochondrial inhibitor and bevacizumab has started in a phase 1b clinical trial of patients with previously-treated metastatic colorectal cancer.
Ivonescimab is being investigated in phase 3 clinical trial against the combination of tislelizumab and chemotherapy.
A coprimary end point in the phase 3 LEAP-010 study will not be met.
Based on positive phase 3 PAPILLON results, an application for a new approval for amivantamab has been filed with the FDA.
Experts believe VAL-083 has the potential to change the way oncologists treat glioblastoma in the future.
Novel agents are now under development for newly druggable targets in patients with solid tumors.
FDA notices NXC-201 for its potential offer a novel mechanism to treat patients with multiple myeloma.
According to Manali Bhave, MD, neratinib plus fulvestrant plus trastuzumab and should be considered as a therapeutic option with clinically meaningful benefit in patients with HER2-mutant metastatic breast cancer.
According to Marcia Brose, MD, PhD, FASCO, interim findings from the phase 3 LIBRETTO-531 trial confirms the benefit of selpercatinib in patients with advanced, RET-mutant medullary thyroid cancer.